Myasthaenia Gravis : Clinical management issues before, during and after pregnancy by Hassan, Ali & Yasawy, Zakia M.
الوهن العضلي الوبيل
 قضايا العالج السريري قبل وأثناء وبعد احلمل
علي ح�سن و زكية حممد ي�ساوي
abstract: Myasthaenia gravis (MG) is an autoimmune neuromuscular disorder which is twice as common 
among women, often presenting in the second and third decades of life. Typically, the first trimester of pregnancy 
and first month postpartum are considered high-risk periods for MG exacerbations. During pregnancy, treatment 
for MG is usually individualised, thus improving its management. Plasma exchange and immunoglobulin therapies 
can be safely used to treat severe manifestations of the disease or myasthaenic crises. However, thymectomies are 
not recommended because of the delayed beneficial effects and possible risks associated with the surgery. Assisted 
vaginal delivery—either vacuum-assisted or with forceps—may be required during labour, although a Caesarean 
section under epidural anaesthesia should be reserved only for standard obstetric indications. Myasthaenic women 
should not be discouraged from attempting to conceive, provided that they seek comprehensive counselling and 
ensure that the disease is under good control before the start of the pregnancy.
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الن�ساء يف  الن�ساء وغالبا ما ي�سيب  �سيوعا بني  اأكرث  ذاتي. وهو  ا�سطراب ع�سبي ع�سلي مناعي  الوبيل هو  الع�سلي  الوهن  امللخ�ص: 
العقدين الثاين والثالث من العمر. عادة، تعترب االأ�سهر الثالثة االأوىل من احلمل و ال�سهر االأول بعد الوالدة فرتات عالية املخاطر لتفاقم 
مر�ص الوهن الع�سلي الوبيل. ويكون عالج هذا املر�ص خالل فرتة احلمل خمتلفا من فرد الأخر مما يح�سن من فر�ص االأ�ستجابة للعالج. 
وميكن عالج املظاهر ال�سديدة للمر�ص او االأنتكا�سة با�ستخدام تغيري البالزما واملعاجلات املناعية ب�سكل اآمن اثناء احلمل. ومع ذلك، ال 
ين�سح با�ستئ�سال الغدة ال�سعرتية ب�سبب االآثار املتاأخرة واملخاطر املحتملة املرتبطة باجلراحة. واأثناء املخا�ص ميكن اجراء الوالدة 
بالطريقة املهبلية العادية اأو ا�ستخدام و�سائل م�ساعدة لها مثل امللقاط او ال�سفاط. كما ميكن اي�سا اجراءعملية قي�رصية حتت التخدير من 
فوق اجلافية عند احلاجة اليها. ال ينبغي تثبيط الن�ساء امل�سابات باملر�ص عن حماولة احلمل مع االأخذ يف االأعتبار تهيئة احل�سول على 
امل�سورة ال�ساملة و�سمان اأن يكون هذا املر�ص حتت ال�سيطرة اجليدة قبل حدوث احلمل.
الكلمات املفتاحية: الوهن الع�سلي الوبيل؛ حمل؛ فرتة ما بعد الوالدة؛ الوهن الع�سلي الوليدي؛ عالج املر�ص.
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Myasthaenia gravis (mg) is an acquired organ-specific autoimmune disease in which autoantibodies are directed against 
the post-synaptic nicotinic acetylcholine receptor 
(AChR) on the neuromuscular endplate of skeletal 
muscles, leading to fatigable weakness of the diaphragm 
and the ocular, oropharyngeal and/or limb muscles.1–3 
In Western countries, the prevalence of MG is 50–125 
cases per million individuals and can present at any age.1 
However, the incidence is twice as common among 
women (ratio: 3:2) and typically occurs during the 
second and third decades of life; in contrast, the disease 
most commonly presents in males during the sixth and 
seventh decades of life.2 The majority of myasthaenic 
patients are seropositive for AChR antibodies, 
while seronegative patients may have antibodies 
to other targets at the neuromuscular junction 
(NMJ), such as muscle-specific kinase (MuSK).3 
Clinical Presentation of 
Myasthaenia Gravis
Patients with MG may have a wide range of clinical 
symptoms. The characteristic presentation is 
fatigability, usually in the form of exercise intolerance, 
with fluctuating skeletal muscle weakness that 
worsens throughout the day and improves with rest.4 
Ocular symptoms of ptosis and diplopia are presenting 
symptoms in over 50% of patients, whereas up to 
15% of patients present with bulbar muscle weakness 
manifesting as dysphagia, dysarthria or difficulty in 
chewing.5 Among patients with ocular myasthenia, 
the progression of the disease to generalised muscle 
weakness usually occurs within two years of onset.5 
A myasthaenic crisis is a life-threatening 
exacerbation of the disease which occurs in 15–20% 
of patients.6 It can sometimes result in severe 
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respiratory and bulbar weakness requiring intubation 
and mechanical ventilation; as such, affected patients 
should be treated in an intensive care unit (ICU).6 Due 
to improvements in the management of myasthaenic 
crises in ICUs over the last four decades, the mortality 
rate has dropped from 75% to the current rate of 
<5%.7 Known triggers of acute MG exacerbations 
include infections, surgery, general anaesthesia, hypo- 
or hyperthyroidism, physical or emotional stress, 
the menstrual cycle, pregnancy, a postpartum state, 
extreme temperatures and exposure to certain 
medications that may increase muscle weakness.6 
In MG, the thymus performs an important role 
in the pathological breakdown of immune tolerance 
towards self-antigens. As such, magnetic resonance 
imaging or computed tomography is advisable to see if 
the thymus is enlarged. Approximately 75% of patients 
with MG have thymic abnormalities.6 Of these, 65% 
have hyperplasia with active germinal centres full of 
plasma cells expressing the AChR α-subunit on their 
surface, resulting in the production of autoantibodies 
to AChRs, while 10% have thymomas, mostly in the 
form of benign tumors.6,8 
Diagnosis of Myasthaenia 
Gravis
A diagnosis of MG is essentially clinical, as fatigability 
is considered a reliable indicator of the disease.6 
Subsequently, serological, electrodiagnostic and pharm- 
acological tests are used to confirm the diagnosis. 
Serum anti-AChR antibodies, which are highly specific 
for MG, are detected in 80–85% of generalised and 
50–60% of isolated ocular MG cases.3,6 Serum anti-
MuSK antibodies are found in 70% of seronegative 
generalised MG cases and should therefore be 
measured when an AChR antibody test is negative.9 
Repetitive nerve stimulation (RNS) and single- 
fibre electromyography (SF-EMG) are electrophys-
iological tests to assess NMJ function. These 
electrophysiological tests should be considered to 
confirm the diagnosis, particularly among seronegative 
patients. At a low frequency (3–5 Hz), RNS shows a 
gradual decrease in the amplitude of the compound 
muscle action potential, with a >10% decrement from 
the fourth response considered pathological.3,6 When 
performed in the weak distal muscles, the test is nearly 
always positive in generalised MG cases; however, 
in patients with isolated ocular myasthaenia, a RNS 
test may be negative in 50% of cases.3 On the other 
hand, SF-EMG is a more sophisticated and highly 
sensitive (95–99%) test for detecting neuromuscular 
transmission abnormalities. Abnormal jitters (>100 ms) 
are found in all myasthaenic patients when 
tested on clinically weak muscles.9 Both of these 
neurophysiological investigations can be performed 
safely on pregnant women.10
The Tensilon test consists of administering 
10 mg of intravenous edrophonium, a short-acting 
acetylcholine esterase inhibitor, under a set protocol to 
improve muscle weakness and sometimes to confirm a 
diagnosis of MG; it is positive in >90% of myasthaenic 
patients, but has a relatively low sensitivity (60%).6 
As such, the results of this test should be interpreted 
in the context of the patient’s clinical features and 
other investigative findings, as the results may also 
be positive for brain stem lesions, third nerve palsy, 
motor neuron disease and mitochondrial myopathies.3 
During testing, intravenous atropine (0.2–4 mg) and 
electrocardiography monitoring facilities should 
be available to counter serious muscarinic side-
effects, like bradycardia or syncope. Administration 
of oral pyridostigmine over several days may result 
in a subjective improvement in muscle strength and 
fatigability which might not otherwise be evident after 
a single dose of edrophonium.11
Treatment of Myasthaenia 
Gravis
Treatment of MG aims to both increase acetylcholine 
neurotransmission at the NMJ and reduce autoantibody 
production. Current treatments include a thymectomy, 
acetylcholinesterase inhibitors (i.e. pyridostigmine 
and neostigmine), immunosuppressants (i.e. cortico-
steroids, azathioprine [AZA], mycophenolate mofetil 
[MMF] and ciclosporin A) and plasma exchange (PE) 
and intravenous immunoglobulin (IG) therapies.2 
Acetylcholinesterase inhibitors act on the para-
sympathetic nervous system and therefore may cause 
hypersecretion, bronchoconstriction and gastro- 
intestinal tract hypermotility; these side-effects 
therefore limit their use in patients with asthma, 
chronic bronchitis and/or diarrhoea.3,12 Pyridostigmine 
is the most commonly prescribed acetylcholinesterase 
inhibitor and acts by inhibiting the synaptic enzyme, 
resulting in an increase in the concentration of 
acetylcholine neurotransmitters at the postsynaptic 
membrane. This form of treatment is purely 
symptomatic, is usually effective in the early stages of 
MG and may be sufficient to treat the mildest form of 
the disease.6
Corticosteroids (e.g. prednisone) are usually 
used in conjunction with pyridostigmine to treat mild 
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refractory disease or moderate-to-severe MG. Initially, 
if administered at a high dose, the patient’s symptoms 
may worsen; therefore, gradual escalation of the steroid 
dose over one to two months is recommended, with 
patients initially prescribed low doses of 10 mg/day 
which are gradually increased up to 60 mg/day.3 Once 
clinical remission is achieved, the dose is tapered over 
several months and is kept on an alternating day cycle.6 
In the long term, nonsteroidal immunosupp-
ressive medications are usually incorporated into the 
medication regimen, such as AZA and MMF. As AZA 
requires between 3–6 months to take effect, it should 
be prescribed concurrently with corticosteroids.6 
In comparison to other immunosuppressants, the 
relatively low-level toxicity and rapid-onset therapeutic 
effects of MMF, which can occur as early as two weeks 
among patients who respond to the therapy, is a 
distinct advantage.6 In addition, MMF has been shown 
to play a potential role in the treatment of refractory 
MG.13 While PE and intravenous IG therapies result 
in rapid improvement for MG patients by removing/
interacting with the circulating autoantibodies against 
AChRs, the effects are unfortunately only temporary 
(approximately 4–10 weeks’ duration).14 As such, 
these therapies are indicated in cases of severe disease, 
myasthaenic crises, perioperative management prior 
to thymic surgery and MG refractory to immuno-
suppressant therapy.6 
A thymectomy is mandatory treatment for 
patients with thymomas, as 30% of thymomas are 
locally invasive.15 Although the therapeutic effects of 
a thymectomy can take years to become apparent, it 
is often associated with an improvement in disease 
severity.6 Therefore, it is frequently performed for 
patients with generalised MG occurring before the 
age of 50 years.9 A recent international randomised 
controlled trial among 126 non-thymomatous patients 
with early- or late-onset MG has confirmed the clear 
benefit over a three-year period of an early thymectomy 
in comparison to medical treatment alone.16 Moreover, 
patients who underwent thymectomies demonstrated 
significant clinical improvement in terms of the 
reduced need for immunosuppressive therapy and 
hospitalisation to treat myasthaenic exacerbations.16 
In total, 80% of MG patients show symptomatic 
improvement after undergoing a thymectomy.17,18 One 
year after a thymectomy, the MG remission rate is 
<20%, although this rises to 50% after 7–10 years.19 The 
Association of British Neurologists have previously 
published detailed clinician guidelines to inform the 
management and treatment of MG patients.20,21
The Effect of Pregnancy on 
Myasthaenia Gravis
Pregnancy has an unpredictable and variable effect 
on the clinical course of MG and the experience of 
previous pregnancies cannot predict the clinical course 
during subsequent pregnancies.22,23 In patients with 
pre-existing MG, the severity of the disease at the 
beginning of the pregnancy may not remain the same 
throughout the rest of the pregnancy; as such, the 
disease can go into remission, become exacerbated or 
remain static.22 However, clinical improvement during 
the second and third trimesters is noted in 
approximately 20–40% of pregnancies, most likely due 
to the immunosuppressive effect of late pregnancy.24 
According to Batocchi et al. and Djelmis et al., 19% 
and 14.5% of MG cases, respectively, worsened during 
pregnancy with a further 28% and 15.9% experiencing 
disease exacerbation during the first six weeks 
postpartum; in comparison, the course of the disease 
remained unchanged throughout the pregnancy in 
39% and 42% of cases, respectively.22,23
In pregnant women, both hypoventilation due to 
respiratory muscle weakness and diaphragm elevation 
due to the growing fetus reduce the capacity of the 
lungs to inflate fully, hence compromising respiratory 
function.10 As such, myasthaenic women should be 
monitored closely throughout their pregnancies for 
breathing problems to avoid respiratory crises which 
would require mechanical ventilation. Moreover, 
changes in blood volume, increased renal clearance, 
frequent vomiting and delayed gastric emptying during 
pregnancy may interfere with the intestinal absorption 
of MG medications and thus necessitate frequent 
dose adjustments.10 Puerperal respiratory and urinary 
tract infections may exacerbate symptoms of MG; 
therefore, prompt diagnosis and treatment of these 
infections is required with antibiotics appropriate 
for use in pregnancy and MG. It is crucial to 
recognise that selected groups of antibiotics—such as 
fluoroquinolones (e.g. moxifloxacin and ciprofloxacin), 
macrolides (e.g. azithromycin and erythromycin) 
and aminoglycosides (e.g. streptomycin and genta-
micin)—may exacerbate myasthaenic-related muscle 
weakness and should hence be avoided.10 The risk 
of mortality for a myasthaenic pregnant woman is 
inversely correlated to the duration of the disease, with 
the highest risk occurring in the first year following 
onset of the disease and reaching its lowest level after 
seven years.24 The physiological stress of pregnancy 
can also precipitate a myasthaenic crisis.24
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Treatment of Myasthaenia 
Gravis During Pregnancy
Therapeutic regimens for pregnant myasthaenic 
women should be individualised and based on 
the severity of the symptoms and distribution of 
muscle weakness in the mother, while considering 
the potential side-effects of the medication on the 
fetus. Myasthaenic patients with the mildest form of 
weakness may only require close follow-up without 
treatment. However, involvement of the bulbar 
and respiratory muscles requires a more aggressive 
treatment approach because of the potential for life-
threatening myasthaenic exacerbations.6 Due to 
its delayed therapeutic effect and possible surgical 
risks, a thymectomy shoud not be considered during 
pregnancy; therefore, both the surgery and thymic 
imaging should be postponed until after delivery to 
avoid teratogenic complications.10 If the pregnancy 
is planned, a thymectomy can be performed before 
conception or after delivery, if required. 
Acetylcholinesterase inhibitors are the drug of 
choice for the symptomatic treatment of MG among 
pregnant women. During pregnancy, pyridostigmine 
is considered safe at a recommended dosage of 
<600 mg/day.9 However, frequent dose adjustments 
may be needed because of frequent vomiting or other 
pregnancy-related changes in intestinal absorption.10 
In cases of severe vomiting, intravenous administration 
may be required; however, this may cause increased 
uterine contractions and premature labour.9 Immuno-
suppressant corticosteroids are effective in the 
majority of pregnant myasthaenic patients and 
should be considered when the severity of symptoms 
necessitates their use.9 However, corticosteroids may 
result in carbohydrate intolerance among pregnant 
women, with an increased risk of cleft palate in 
newborn infants when used by their mothers during 
the first trimester.25 As such, corticosteroids should 
be maintained at the lowest possible dose whenever 
possible. Premature rupture of the membranes and 
preterm delivery have also been associated with high 
doses of corticosteroids.24 In addition, the transient 
worsening of myasthaenic symptoms has been 
reported to occur with the initiation of corticosteroid 
therapy.4
While the initiation of immunosuppressive drugs 
should be avoided before and during pregnancy, the 
risk of triggering a myasthaenic crisis or exacerbation 
by dose reduction or discontinuation in pregnant 
myasthaenic women needs to be balanced against 
the teratogenic risk to the fetus.21 However, recent 
best practice guidelines support the use of AZA 
at therapeutic dosages throughout pregnancy and 
during the breastfeeding period.21,26 Although AZA 
crosses the placenta, the immature fetal liver has 
a deficiency of the enzyme responsible for the 
conversion of AZA to its active metabolites; hence, the 
fetus is relatively protected from the harmful effects 
of the drug.21 Nevertheless, reversible leucopenia, 
thrombocytopaenia, anaemia, thymic atrophy and 
decreased IG levels have been reported among infants 
exposed to AZA.24,27 In addition, newborns whose 
mothers were treated with AZA may also have an 
increased risk of myelo- and immunosuppression.24 
Although considered safe for use during pregnancy 
and breastfeeding, ciclosporin A may cause pre-
maturity, spontaneous abortions and low birth weight 
among newborn infants.21,24 In contrast, MMF is 
considered teratogenic, causing a clinical syndrome 
which includes hypoplastic nails, shortened fifth 
fingers, oral cleft, microtia, diaphragmatic hernia and 
micrognathia.21 Contraception is required before, 
during and for up to six weeks after MMF therapy.28 
Treatment of Acute 
Myasthaenic Exacerbations 
During Pregnancy
Both PE and intravenous IG therapies have been 
proven to be effective, safe and well tolerated during 
pregnancy.10 Although these therapies result in a 
rapid improvement in MG symptoms, the benefits are 
short-lived and retreatment may be required; as such, 
they should be reserved for patients experiencing 
myasthaenic crises or to manage severe myasthaenic 
symptoms when conventional therapy has failed.4,14 
However, the hyperviscosity and volume overloading 
associated with intravenous IG may be dangerous 
during pregnancy and should be carefully monitored.24 
During PE sessions, the occurrence of hypotension 
must also be carefully monitored and corrected; 
placing the patient in a left lateral decubitus position 
may be helpful. In addition, PE may cause premature 
labour by removing the circulating hormones vital for 
the integrity of pregnancy.24 Although both treatment 
modalities have been found to have equivalent efficacy 
in the treatment of myasthaenic exacerbations, 
PE should be considered a second-line option to 
intravenous IG therapy due to its effect on blood 
volume, circulating hormones and coagulation factor 
changes in pregnancy.2 Table 1 summarises the safety 
and potential side-effects of medications used to treat 
MG during pregnancy.10,21,24
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Labour and Delivery 
Considerations for 
Myasthaenia Gravis Cases
Typically, MG does not affect the first stage of labour 
because of the involvement of smooth muscles. In 
contrast, during the second stage, maternal fatigability 
may be pronounced because the voluntary striated 
muscles are involved.24 At this point, the patient 
may become exhausted, potentially precipitating a 
myasthaenic crisis; hence, the obstetrician should 
be prepared for an assisted vaginal delivery if necessary 
(e.g. via vacuum extraction or with forceps).10,23 
Acetylcholinesterase inhibitors can minimise 
myasthaenic fatigue during labour and should be 
administered parenterally to avoid erratic gastro-
intestinal absorption.24 Intravenous doses of pyrido-
stigmine and neostigmine are equivalent to about 
one-thirtieth of the usual oral dose.29 Neostigmine 
(1.5 mg intramuscularly or 0.5 mg intravenously every 
3–4 hours) is preferrable to pyridostigmine, which 
may cause the formation of sterile abscesses.24 Surgery 
is very stressful and can cause acute worsening of 
myasthaenic symptoms; therefore, a Caesarean section 
procedure should be reserved only for standard 
obstetric indications.
As myasthaenic patients are especially sensitive to 
certain anaesthetic drugs, an anaesthesiologist should 
be consulted at the beginning of the pregnancy.24 
Epidural anaesthesia not exceeding the 10th thoracic 
veterbra level is preferrable in both vaginal and 
surgical deliveries to provide adequate analgaesia.2 
However, this should be confined to amide-type 
local anaesthetic agents (e.g. lidocaine, mepivacaine 
and bupivacaine) because these agents do not affect 
myasthaenia, whereas ester-type medications (such as 
benzocaine, tetracaine and procaine) should be avoided 
because of the risk of exacerbation of the underlying 
myasthaenia.2 Nonsteroidal anti-inflammatory drugs 
(such as ketorolac tromethamine) and paracetamol 
(acetaminophen) can be used for postpartum or 
postoperative pain, while narcotic analgaesic agents 
that may cause respiratory depression should 
be avoided.4
Magnesium sulphate inhibits acetylcholine release 
by blocking the presynaptic calcium influx at the 
nerve terminals; however, it is contraindicated for 
Table 1: Maternal and fetal side-effects and safety of drugs used to treat myasthaenia gravis during pregnancy10,21,24
Drug Maternal side-effects FDA 
category*
Teratogenic side-effects Safety 
during 
pregnancy
Pyridostigmine Abdominal cramps, excessive oral and 
bronchial secretions, diarrhoea and 
bradycardia
C Respiratory distress and 
microcephaly (dose >600 mg/day)
Safe
Prednisone Weight gain, hyperglycaemia, gastritis, 
gastric ulcers, mood changes, 
osteoporosis and myopathy
C Cleft palate Safe
Azathioprine Bone marrow suppression, 
gastrointestinal disturbances, 
hepatotoxicity, leukaemia and possible 
increased risk of lymphomas
D Reversible leukopaenia, anaemia, 
thrombocytopaenia, thymic 
atrophy, sporadic congenital 
defects such as cerebral palsy, 
cerebral haemorrhage and 
cardiovascular defects
Safe†
Ciclosporin Renal toxicity, hypertension, seizures, 
myopathy, tremors, increased body 
hair and gingival hyperplasia
C Prematurity, low birth weight, 






Gastrointestinal disturbances, white 
blood count reduction and a possible 
increased risk of lymphomas and 
other malignancies such as skin cancer
D Pregnancy loss in the first 
trimester, cleft lip and 
palate, micrognathia, ocular 
hypertelorism, microtia and 





Headache, aseptic meningitis, acute 





Hypotension, tachycardia, electrolyte 
imbalances, sepsis and venous 
thrombosis
N/A Unknown Safe
FDA = Food and Drug Administration; N/A = not applicable.
*FDA pregnancy risk classification using the following scores: A (no fetal risk), B (no evidence of risk in humans, hence the chance of fetal harm is 
remote but possible), C (chance of fetal harm, but the potential benefits to the mother outweigh the risk) and D (evidence of fetal risk, but the potential 
benefits to the mother outweigh the risk).
†Recent guidelines from the UK consider these immunosuppressive agents safe during pregnancy and breastfeeding.21
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use in the management of eclampsia in myasthaenic 
women since it can cause acute worsening of MG 
symptoms.10 Levetiracetam and valproic acids are 
acceptable alternatives for seizure prophylaxis, while 
phenytoin should be reserved for refractory seizures 
because it can potentially exacerbate myasthaenic-
related weakness.4 The treatment of hypertension is 
a cornerstone of pre-eclampsia management; methyl-
dopa and oral hydralazine can be considered the initial 
drugs of choice to control non-severe hypertension, 
while intravenous hydralazine should be used to reduce 
acute blood pressure in severe hypertensives (systolic 
pressure of >160 mmHg or diastolic pressure of 
>110 mmHg).30 However, in comparison to hydralazine, 
intravenous urapidil has shown better tolerability 
and controllability and is a promising alternative.31 
Both β-blockers and calcium channel blockers can 
potentially worsen myasthaenic symptoms and thus 
should be avoided.30
Neonatal Considerations for 
Myasthaenia Gravis Cases
Among neonates whose mothers have MG, between 
10–20% develop transient neonatal MG (TNMG) 
shortly after birth because of the transplacental 
passage of maternal AChR antibodies.10,32 Commonly, 
this occurs in cases wherein the mothers are positive 
for AChR and/or anti-MuSK antibodies, but is rarely 
seen in neonates with seronegative myasthaenic 
mothers.33,34 Symptoms of TNMG appear within the 
first few days of life, most commonly 12–48 hours 
after delivery and characteristically resolve within four 
weeks (18–21 days); occasionally, symptoms persist 
for as long as four months.9,34,35
Symptoms of TNMG include a weak cry, ptosis, 
facial weakness, poor sucking, generalised hypotonia 
and respiratory distress; however, the severity of 
these symptoms differs from newborn to newborn, 
with some showing only mild hypotonia and others 
requiring mechanical ventilation due to significant 
breathing problems.24,32,34 Thus, neonatal ICU facilities 
should be available at the time of delivery and infants 
born to myasthaenic mothers should be carefully 
monitored during their first 48–72 hours for signs of 
respiratory difficulty and muscle weakness. Ventilatory 
support and pyridostigmine (0.5–1.0 mg/kg in divided 
doses) should be administered as necessary until the 
neuromuscular symptoms have resolved, with PE 
therapy to be considered in more severe cases.10
Rarely, the babies of myasthaenic mothers 
may develop arthrogryposis multiplex congenita, a 
syndrome characterised by nonprogressive contract-
ures of multiple joints throughout the body at the 
time of birth.32 A likely mechanism that leads to 
the development of this condition is reduced fetal 
movements in utero, possibly due to the placental 
transfer of maternal AChR antibodies that selectively 
inhibit fetal AChR function.32 Infants born to mothers 
with a high quantity of AChR antibodies in relation to 
the fetal γ-subunit of AChR may develop severe fetal 
arthrogryposis.21 Ultrasonography should therefore 
be performed to detect this condition in utero by 
monitoring fetal movement.
Postpartum Considerations for 
Myasthaenia Gravis Cases
During the first postpartum month, close follow-
up is recommended to monitor the potential 
exacerbation of myasthenic symptoms such as 
weakness and respiratory distress. Breastfeeding is 
not contraindicated in myasthaenic mothers, but 
can worsen cases of TNMG as AChR antibodies 
are secreted in breast milk; it is therefore advisable 
to avoid breastfeeding symptomatic newborns.24 
Symptoms of MG also intensify in the setting of 
infection; therefore, myasthaenic mothers should be 
advised to promptly report any symptoms consistent 
with infections (e.g. urinary, respiratory tract, uterine 
or wound infections).2 
In lactating myasthaenic mothers, choosing a 
medication regimen is challenging because of the 
potential teratogenic risks to the infant. Pyridostigmine 
is considered safe during lactation unless high doses are 
required, which may cause gastrointestinal symptoms 
in breastfed infants. Glucocorticoids and AZA can also 
be used safely by nursing mothers; however, for infants 
breastfeeding from mothers taking AZA, it is advisable 
to monitor complete blood count and conduct a liver 
function test.21,24 Breastfeeding is contraindicated in 
myasthaenic women taking MMF.2
Infant care can be particularly difficult for 
myasthaenic mothers; the increased fatigue associated 
with a lack of sleep due to nighttime feedings and the 
increased exertion related to caring for a newborn may 
cause a worsening of MG symptoms. In patients for 
whom immunosuppressive therapy is to be initiated 
or restarted after delivery, contraceptive counselling 
is strongly recommended. An effective contraceptive 
should be prescribed at least four weeks before 
immunosuppressive therapy begins and should be 
maintained for six months before a new pregnancy.10 
The cyclic withdrawal of oral contraceptives is well 
documented to cause exacerbation of myasthaenic 
symptoms.2 Continuous hormonal contraception or 
an intrauterine device may therefore be better options 
for myasthaenic women.2
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Pre-Pregnancy Counsell ing 
for Women with Myasthaenia 
Gravis
All myasthaenic women who are considering having 
children should be advised to undergo pre-pregnancy 
counselling with a neurologist before conception to 
optimise their myasthaenic status, reduce the use of 
immunosuppressive medications and assess the need 
for a thymectomy. During counselling, patients should 
also receive information about the risks of pregnancy 
and make an informed decision based on the most 
current data available. A patient who has been newly 
diagnosed with ocular MG potentially risks developing 
severe generalised MG within two years.5 It is therefore 
prudent to delay conceiving during this period so as 
to avoid potential worsening of the disease due to 
pregnancy. 
As pyridostigmine is safe for use during pregnancy 
and among women with the mildest form of the 
disease, it can be initiated as a symptomatic treatment 
even before conception for women planning to get 
pregnant.9 However, immunosuppressive medications 
other than corticosteroids and AZA should typically 
be avoided because of their teratogenic risk.21 A pre-
conception thymectomy might decrease the need for 
such medications during the course of the pregnancy; 
however, the patient should be informed that it may 
take years before the full therapeutic effects of the 
surgery become evident.6 The patient should also be 
cautioned that MG severity at the beginning of their 
pregnancy does not predict the same disease course 
throughout the rest of the pregnancy and that the 
course of previous pregnancies does not forecast the 
outcome of any subsequent pregnancies.10,22,23 It should 
also be noted that the absence of symptoms of MG 
before or during pregnancy does not guarantee the 
delivery of a healthy infant.36 As such, the possibility 
of their newborn developing arthrogryposis multiplex 
congenita or TNMG should always be discussed 
with MG patients who wish to have children. Table 2 
summarises recommendations for management among 
women with MG of childbearing age.21
Table 2: Recommendations for the management of women of childbearing age with myasthenia gravis21
Time period Recommendations
Pre-pregnancy • Counselling by a neurologist 
• Effective contraception advice for pregnacy planning
• Advice on the safety of different MG treatments during pregnancy (i.e. prednisone, AZA, pyridostigmine 
   and ciclosporin) 
• MG drugs should not be discontinued without medical consultation
• Thyroid function tests
• Thymectomy (if necessary)
During pregnancy • Counselling on the possible teratogenic effects of immunosuppressive agents (i.e. methotrexate or MMF) 
   as well as the risk of disease exacerbation with abrupt withdrawal
• Interdisciplinary care from neurologists, obstetricians and anaesthesiologists
• Consultation with an obstetric anaesthesiologist before the early third trimester
• Prompt treatment with suitable antibiotics for infections (i.e. UTIs)
• Fetal monitoring
• Thymectomy is not advised
During labour and 
delivery
• Delivery at hospitals/birth centres with on-site general ICU and NICU facilities 
• Multidisciplinary team from an obstetrician, obstetric anesthesiologist, neonatologist and neurologist
• Women with well-controlled MG should aim to have a vaginal delivery with spontaneous onset of labour 
• Caesarean deliveries should be performed only if necessary
• Intravenous hydrocortisone should be given in stress doses (i.e. 100 mg three times a day) to patients on 
   long-term oral steroids
• Medications to treat preeclampsia, eclampsia and  postpartum pain should be carefully selected
• Treatment with magnesium sulphate should be avoided 
• Epidural analgaesia is preferable to general anaesthesia
Postpartum • Breastfeeding should be encouraged for patients receiving pyridostigmine, prednisone or AZA
• Early consultation with a neurologist 
• All infants should be monitored for at least 48 hours for symptoms of TNMG, preferably in the NICU
• For infants with TNMG, pyridostigmine should be prescribed until the neuromuscular symptoms resolve
• Intravenous IG and PE therapies should be considered in severe TNMG cases
MG = myasthaenia gravis; AZA = azathioprine; MMF = mycophenolate mofetil; UTI = urinary tract infection; ICU = intensive care unit; 
NICU = neonatal ICU; TNMG = transient neonatal myasthaenia gravis; PE = plasma exchange; IG = immunoglobulin.
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Conclusion
Treatment of MG during pregnancy is challenging 
because the disease course is unpredictable and 
highly variable. Medication regimens must balance 
the teratogenic risk to the fetus with the potential 
therapeutic benefits to the myasthaenic patient. 
Immunosuppressive therapy should be discontinued 
before conception, although corticosteroids, AZA 
and intravenous IG and PE therapies can be used 
safely throughout the pregnancy. Forceps or vacuum 
extraction is often necessary to reduce the length of the 
second stage of labour, although a Caesarean delivery 
should be conducted only if necessary according 
to standard obstetrical indications. Intensive care 
facilities should be available for newborns due to the 
risk of TNMG. Throughout their pregnancy, during 
delivery and in the postpartum period, women with 
MG require personalised care from a multidisciplinary 
team comprising neurologists, obstetricians, neonato-
logists and anaesthesiologists.
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